Potassium

Evidence Level: L1

Predicted Indications: 5

Potassium

Pharmacist Assessment Report

Potassium: From an Unspecified Original Indication to Hypertensive Disorder

One-Sentence Summary

Potassium is an essential electrolyte, marketed in Australia as oral powder products (Kindergen and Renastart), and the approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be useful for hypertensive disorder, with a score of 0.9916. The evidence includes 23 registered clinical trials and 20 publications, but most trials involve potassium only as a salt component of other drugs. The strongest support comes from meta-analyses of potassium intake and blood pressure.

Quick Overview

Item	Content
Original Indication	Not available in the data compiled for this report
Predicted New Indication	Hypertensive disorder
TxGNN Prediction Score	0.9916
Evidence Level	L1 (see note below)
Australia Market Status	Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	2 (valid: 2)
Recommended Decision	Proceed with Guardrails

Note on evidence level: L1 is the level assigned in the compiled data. It rests on the Phase 3 and meta-analytic evidence for potassium intake. Most of the listed Phase 3 trials test other drugs (such as losartan potassium), so the directly relevant evidence is weaker than the label suggests.

Why is This Prediction Reasonable?

Detailed mechanism of action data for this product is not available in the data compiled for this report. Based on the published literature, increased potassium intake promotes sodium excretion (natriuresis), may relax blood vessels through effects on potassium channels and Na+/K+-ATPase in endothelial and vascular smooth muscle cells, and blunts the blood-pressure-raising effect of sodium.

Dose-response meta-analyses of randomised controlled trials, together with a systematic review and meta-analysis, support a blood-pressure-lowering effect of higher potassium intake. This is a nutritional and electrolyte mechanism, so the relationship to the original indication is unclear. The original indication could not be determined from the data available.

Other predicted indications (pulmonary hypertension, malignant renovascular hypertension and malignant hypertensive renal disease) have little or no direct clinical evidence. They should be treated as computational predictions only and kept on hold.

Clinical Trial Evidence

Most registered trials involve potassium only as a counter-ion (for example, losartan potassium) and are not direct evidence. The trials most relevant to potassium itself are listed first.

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00000509	Phase 3	Completed	Not reported	Sodium reduction with and without potassium supplementation for blood pressure control in hypertensive men (most direct evidence)
NCT03809884	Phase 3	Completed	7	Diet versus supplement to raise potassium intake; very small sample
NCT02959931	Not applicable	Completed	33	Acute vascular effects of a high-potassium meal in hypertensive patients
NCT00949585	Not applicable	Completed	29	Two levels of potassium intake in chronic kidney disease; blood pressure and safety
NCT02697708	Phase 1/2	Unknown	40	Potassium from supplement, potatoes or French fries; effect on potassium retention and blood pressure
NCT00000501	Phase 2	Completed	Not reported	Hypertension Prevention Trial feasibility study: sodium reduction with or without increased potassium
NCT01074918	Phase 1/2	Withdrawn	0	Potassium-magnesium citrate versus potassium chloride; never enrolled
NCT01302691	Phase 3	Completed	327	Losartan potassium/hydrochlorothiazide/amlodipine combination in Japanese patients; potassium is a salt component only
NCT00949884	Phase 4	Completed	941	Olmesartan versus losartan potassium; potassium is a salt component only
NCT00480805	Phase 3	Completed	312	Hyzaar (losartan potassium/HCTZ) versus ramipril in diabetic hypertension; potassium is a salt component only

Further registered trials in the compiled data are antihypertensive drug studies, bioequivalence studies or other unrelated designs, and are not evidence for potassium itself. No ANZCTR identifiers are available in the compiled data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32500831	2020	Meta-analysis of RCTs	J Am Heart Assoc	Dose-response meta-analysis of potassium supplementation (≥4 weeks) and blood pressure
23558164	2013	Systematic review and meta-analysis	BMJ	Effect of increased potassium intake on cardiovascular risk factors and disease
37772757	2024	Review	Am J Hypertens	State-of-the-art review of potassium and hypertension
9624886	1998	Review	Nutr Rev	Meta-analysis supports a role for increased potassium intake in preventing and treating hypertension
10979053	2000	Review/guideline	Arch Intern Med	Guidelines for potassium replacement in clinical practice
35045721	2022	Clinical study	Hypertension	Potassium-induced natriuresis in hypertensive postmenopausal women, compared with hydrochlorothiazide
41263071	2026	Analysis of trial data	Hypertension	Consistency of blood pressure response to potassium-enriched salt in the China Salt Substitute Study
39543422	2025	Commentary	Hypertens Res	Antihypertensive combinations and potassium homeostasis
24721891	2015	Review	Clin J Am Soc Nephrol	Regulation of potassium homeostasis
33688065	2022	Review	Postgrad Med J	Diuretic-induced hypokalaemia: prevalence and management

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 8587Y	Kindergen	Oral powder 400 g	Not available
ARTG 2870C	Renastart	Oral powder 400 g, 6	Not available

Safety Considerations

Specific warnings, contraindications and drug interaction data were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

From the repurposing assessment, the main concern is hyperkalaemia. This is particularly relevant in:

Chronic kidney disease or impaired potassium handling
Patients taking RAAS inhibitors (ACE inhibitors, ARBs) or potassium-sparing diuretics

Serum potassium and renal function would need monitoring.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Meta-analyses of randomised trials support a blood-pressure-lowering effect of higher potassium intake, but direct trial evidence for these specific products is limited. Most listed trials only involve potassium salts of other drugs, and the hyperkalaemia risk is significant in common hypertensive populations. The other four predicted indications should remain on Hold, because they rest on prediction scores or indirect mechanistic literature alone.

To proceed, the following is needed:

Approved indication text and PI safety information (warnings, contraindications, interactions) for the Australian products
Mechanism of action data from DrugBank
Clarification of the original indication and its relationship to hypertension
A patient selection and monitoring plan (serum potassium, renal function, concomitant RAAS inhibitors and potassium-sparing diuretics)
Review of dose and formulation, since the Australian products are oral powders and may not suit chronic blood pressure management
Adequately powered trials of potassium supplementation specifically in hypertension, ideally including Australian patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.